Stadiul cunoaşterii.... - Gr.T. Popa

More documents

Recommendations

Info

Corelaţii clinice,imunohistochimice şi morfopatologice în unele tumori de ovar Coordonator ştiinţific:Prof.Dr.Zenovia Florentina Pricop __________________________________________________Doctorand:Ioana Buda BIBLIOGRAFIE SELECTIVA 1. Aida H, Takakuwa K, Nagata H, et al.: Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4 (1): 235-40, 1998. 2. Amalinei C.,Histologie speciala, Ed.Junimea, Seria Esculap, 2005, pag.216-228. 3. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008. Also available online. Last accessed October 1, 2008. 4. Anreder MB, Scott MF, Merogi A, Halabi S, Marrogi AJ – p53, c-erB2, and PCNA status in benign, proliferative, and malignant ovarian surface epithelial neoplasms, Archi Pathol Lab Med, 1999;123(4):310-316 5. Anttonen M, Unkila-Kallio L, Leminen A, et al. High GATA-4 expression associates with aggressive behavior, wHEReas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab 2005;90:6529–35. 6. Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R – Clinical Significance of Apoptosis-Related Factors p53, Mdm2 and Bcl-2 in Advanced Ovarian Cancer, Journal of Clinical Oncology, 1999;17(7):2061- 2072 7. Baker PM, Oliva E. Immunohistochemistry as a tool in the different diagnosis of ovarian tumors: an update. Int J Gynecol Path 2005;24:39–55. 8. Ballotta MR, Bianchini E, Borghi L, et al. Clear cell carcinoma simulating the ‘endometrioid-like variant’ of yolk sac tumor. Pathologica. 1995;87: 87–90 9. Bamberger ES, Perrett CW – Angiogenesis in epithelian ovarian cancer, Molecular Pathology, 2002;55:348-359 10. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol. Feb 2003;15(1):51-5. 11. Bast R.C. Jr., Yu Y., Xu F.-J., Molecular approaches to management of epithelial ovarian cancer, Int J Gynecol cancer, 2000, 10 (suppl. 1): 2-7 12. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. Nov 1981;68(5):1331-7 13. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. Oct-Dec 1998;13(4):179-87. 14. Bell K.A., Kurman R.J., A clinicopathologic analysis of atypical proliferative (cu potential malign scazut) tumors and well differentiated endometrioid adenocarcinomas of the ovary, Am J Surg Pathol, 2000, 24 (110): 1465-1479 15. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinne GR, Soper JT, Dodge R, Clarck Pearson & Merks P 1990 Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Research 50 4087–4091. 16. Berek J and Hacker N. Practical Gynecologic Oncology, 4th ed. 2005. 17. Bigbee W, HERberman RB. Tumor markers and immunodiagnosis. In: Bast RC Jr., Kufe DW, Pollock RE, et al., editors. Cancer Medicine. 6th ed. Hamilton, Ontario, Canada: BC Decker Inc; 2003. 18. Bjorkholm E, Silfversward C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981;11:261–74. 76
Corelaţii clinice,imunohistochimice şi morfopatologice în unele tumori de ovar Coordonator ştiinţific:Prof.Dr.Zenovia Florentina Pricop __________________________________________________Doctorand:Ioana Buda 19. Boyd J., Sonoda Y., Federici M.G., Clinicopathologic features of BRCA-linked and sporadic ovarian cancer, JAMA, 2000, 283: 2260-2265 20. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. Feb 1999;17(2):501-8. 21. Burger CW, van Doorn HC, van der Valk P & Bonfre`r HMG 1999 Oestrogen, progesterone and androgen receptors in ovarian neoplasm; correlation between immunohistochemical and biochemical receptor analysis. International Journal of Gynecological Cancer 9 17. 22. Burger, H. G., Baillie, A., Drummond, A. E., Healy, D. L., Jobling, T., Mamers, P. et al. (1998). Inhibin and ovarian cancer. J. Reprod. Immunol. 39(1–2), 77–87. 23. Burger, H. G., Robertson, D. M., Cahir, N., Mamers, P., Healy, D. L., Jobling, T. et al. (1996). Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin. Endocrinol. (Oxf.);44(4), 413–418. 24. Buţureanu S. Patologie ginecologică benignă. Institutul European 2004. 25. Campbell S, Bhan V, Royston J, et al. Screening for early ovarian cancer. Lancet 1988;1:710-1. 26. Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for early ovarian cancer BMJ 1989;299:1363-7. 27. Cannistra SA: Cancer of the ovary. N Engl J Med 329 (21): 1550-9,1993.Carmeliet P, Jain RK. Angiogenesis in cancer and otHER disease. Nature 2000;407:249–57. 28. Carlson JK, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 121(2): 124-32, Jul 1994. 29. Carmeliet P, Jain RK. Angiogenesis in cancer and otHER disease. Nature 2000;407:249–57. 30. Casazza S.-L’espressione della fosfoproteina P53 in patologia,Pathologica,1993,85:321-334 31. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol. 2002;117:944–951 32. Chan W. Y., Cheung K. K., Schorge J. O., Huang L. W., Welch W. R., Bell D. A., Berkowitz R. S., Mok S. C. – Bcl-2 and p53 Proteins Expression, Apoptosis and p53 Mutation in Human Epithelial Ovarian Cancers, American Journal of Pathology, 2000;156: 409- 417 33. Charpin C, Bhan AK, Zurawski VR Jr, Scully RE. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an 34. immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Pathol. 1982;1(3):231-45. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. Jan 15 2006;66(2):1181-90.Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol. Jul 1988;72(1):23-7. 35. Cuatrecacas M., Villanueva A., Matias-Guiu X. Prat J., K-ras mutation in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases, Cancer 1997; 79: 1581-1586 36. Czernobilsky B, Moll R, Levy R, et al. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulose and rete ovarii cells of the human ovary. Eur J Cell Biol 1985;37:175–90. 37. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin, I. Science 1994;265:1582–4. 77
Page 1 and 2:
Corelaţii clinice,imunohistochimic
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26: Corelaţii clinice,imunohistochimic
Page 75: Corelaţii clinice,imunohistochimic
Page 81: Corelaţii clinice,imunohistochimic
show all

Stadiul cunoaşterii.... - Gr.T. Popa

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?